You just read:

CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter

News provided by

CytoSorbents Corporation

Aug 21, 2018, 09:06 ET